Last updated on April 2019

Stroke Imaging Package Study of Intracranial Atherosclerosis ( SIPS-ICAS )


Brief description of study

A prospective, multicenter, observational study to explore the dynamic changes of intracranial plaque under aggressive medical management and its relation with stroke recurrence.

Detailed Study Description

  1. First-ever stroke patients attributed to intracranial artery stenosis (> 50%) within 7 days after onset will be prospectively enrolled in our study and undergo new imaging technique package assessment at baseline.
  2. The imaging technique package includes conventional cranial MRI T1,T2,T2 FLAIR,DWI, and ADC), cranial magnetic resonance angiography (MRA), intracranial vessel wall imaging and susceptibility weighted imaging (SWI).
  3. Enrolled patients will receive aggressive medical management consisted of Aspirin (100 mg daily) and Clopidogrel (75 mg daily) for 3 months and Crestor (20mg daily) for at least 6 months as well as traditional risk factors management.
  4. Patients were followed up for mRS score, stroke recurrence, medication compliance and laboratory examination including blood routine tests, liver functions and creatine kinase at 3 months, 6 months and 12 months after stroke onset. Additionally, patients are required to retake new HRMRI imaging of brain at 6 months.Remote patient education by We-Chat will be performed.
  5. Our study aims to explore the dynamic changes of intracranial plaque under aggressive medical management using new imaging package and establish a risk model to predict stroke recurrence and unfavorable outcome in patients with symptomatic intracranial stenosis.

Clinical Study Identifier: NCT03719820

Find a site near you

Start Over